(Q44101920)

29 November 2017

Phase II trial of thalidomide in renal-cell carcinoma (English)

1 reference

29 November 2017

phase II clinical trial

0 references

0 references

4

1 reference

29 November 2017

B Escudier

1

1 reference

29 November 2017

N Lassau

2

1 reference

29 November 2017

D Couanet

3

1 reference

29 November 2017

F Mesrati

5

1 reference

29 November 2017

S Leborgne

6

1 reference

29 November 2017

A Garofano

7

1 reference

29 November 2017

C Leboulaire

8

1 reference

29 November 2017

N Dupouy

9

1 reference

29 November 2017

A Laplanche

10

1 reference

29 November 2017

1 July 2002

1 reference

29 November 2017

1 reference

29 November 2017

13

1 reference

29 November 2017

1029-1035

1 reference

29 November 2017

7

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDF213

29 November 2017

1 reference

Observations on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2 to patients with metastatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDF213

Angiogenesis in cancer, vascular, rheumatoid and other disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDF213

Thalidomide is an inhibitor of angiogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDF213

Effect of thalidomide on tumour necrosis factor production and anti-tumour activity induced by 5,6-dimethylxanthenone-4-acetic acid

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDF213

Effects of thalidomide and related metabolites in a mouse corneal model of neovascularization

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDF213

Antitumor activity of thalidomide in refractory multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDF213

Continuous low dose Thalidomide: a phase II study in advanced melanoma, renal cell, ovarian and breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDF213

Nonparametric Estimation from Incomplete Observations

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDF213

Estimation of confidence limits for the cumulative probability of survival in life table analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDF213

Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II. analysis and examples

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDF213

Response rate accuracy in oncology trials: reasons for interobserver variability. Groupe Français d'Immunothérapie of the Fédération Nationale des Centres de Lutte Contre le Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDF213

Tumor angiogenesis: molecular pathology, therapeutic targeting, and imaging

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDF213

Thalidomide neuropathy: a clinical electrophysiological, and histological follow-up study

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDF213

Increased risk of deep-vein thrombosis in patients with multiple myeloma receiving thalidomide and chemotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDF213

Dynamic Helical CT of Breast Tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDF213

21 January 2018

Identifiers

DOI

10.1093/ANNONC/MDF213

1 reference

29 November 2017

1 reference